Philippe Moris

4.2k citations
54 papers · 2.8k · h-index 30

Impact in

Papers in

  • Epidemiology 33
    • Influenza Virus Research Studies 12
    • Respiratory viral infections research 10
    • Hepatitis B Virus Studies 8
  • Immunology 25
    • Immunotherapy and Immune Responses 10
Co-authors
Opokua Ofori‐Anyinam (15 shared papers)Emmanuel Hanon (4 shared papers)Geert Leroux‐Roels (10 shared papers)Joe Cohen (12 shared papers)Frédéric Clément (6 shared papers)Erik Jongert (11 shared papers)Francis Dessy (3 shared papers)Marie‐Ange Demoitié (9 shared papers)
Journals
Vaccine (11 papers)Human Vaccines & Immunotherapeutics (7 papers)Tuberculosis (3 papers)PLoS ONE (3 papers)Clinical Infectious Diseases (2 papers)
Partner nations
BelgiumUnited StatesUnited Kingdom

In The Last Decade

Philippe Moris

53 papers receiving 2.7k citations

Peers

Philippe Moris
Comparison fields: 5 of 99
  • Immunology 1.4k
  • Infectious Diseases 918
  • Virology 205
  • Epidemiology 1.3k
  • Microbiology 140
Replace Patricia A. Darrah with:
Patricia A. Darrah United States
Frédéric Clément Belgium
Ricardo E. Tascon United Kingdom
Donata Medaglini Italy
Nigel Temperton United Kingdom
Susan L. Baldwin United States
Thomas Ebensen Germany
Tamara Berthoud United Kingdom
George H. Lowell United States
Chikara Aizawa Japan
Philippe Moris relative to Patricia A. Darrah United States Patricia A. Darrah's profile →
Citations per field
00.5×1.5×
Patricia A. Darrah · 1×
Citations per year

Countries citing papers authored by Philippe Moris

Since Specialization
Citations

This map shows the geographic impact of Philippe Moris's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Philippe Moris with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Philippe Moris more than expected).

Fields of papers citing papers by Philippe Moris

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Philippe Moris. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Philippe Moris. The network helps show where Philippe Moris may publish in the future.

Co-authors

The 25 scholars most cited alongside Philippe Moris, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Philippe Moris Line = papers co-authored together Philippe Moris links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 54 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only
Vaccine ·Sandro Giannini, Emmanuel Hanon, Philippe Moris, Maxime Vanmechelen, S. Morel, Francis Dessy, Marc Fourneau, Brigitte Colau, Jon Suzich, G LOSONKSY
2006391
2
Randomized, Double‐Blind, Phase 2a Trial of Falciparum Malaria Vaccines RTS,S/AS01B and RTS,S/AS02A in Malaria‐Naive Adults: Safety, Efficacy, and Immunologic Associates of Protection
The Journal of Infectious Diseases ·Kent E. Kester, James F. Cummings, Opokua Ofori‐Anyinam, Christian F. Ockenhouse, Urszula Krzych, Philippe Moris, Robert Schwenk, Robin A. Nielsen, Zufan Debebe, Evgeny Pinelis, Laure Juompan, Jack Williams, Megan Dowler, V. Ann Stewart, Robert A. Wirtz, Marie‐Claude Dubois, Marc Lievens, Joe Cohen, W. Ripley Ballou, D. Gray Heppner, (unknown)
2009369
3
Vaccine Adjuvant Systems containing monophosphoryl lipid A and QS21 induce strong and persistent humoral and T cell responses against hepatitis B surface antigen in healthy adult volunteers
Vaccine ·Pierre Vandepapelière, Yves Horsmans, Philippe Moris, Marcelle Van Mechelen, Michel Janssens, Marguerite Koutsoukos, Pascale Van Belle, Frédéric Clément, Emmanuel Hanon, Martine Wettendorff, Nathalie Garçon, Geert Leroux‐Roels
2008168
4
H5N1 Influenza Vaccine Formulated with AS03A Induces Strong Cross-Reactive and Polyfunctional CD4 T-Cell Responses
Journal of Clinical Immunology ·Philippe Moris, Robbert van der Most, Isabel Leroux‐Roels, Frédéric Clément, Mamadou Dramé, Emmanuel Hanon, Geert Leroux‐Roels, Marcelle Van Mechelen
2010123
5
Improved CD4+ T cell responses to Mycobacterium tuberculosis in PPD-negative adults by M72/AS01 as compared to the M72/AS02 and Mtb72F/AS02 tuberculosis candidate vaccine formulations: A randomized trial
Vaccine ·Isabel Leroux‐Roels, Sheron Forgus, Fien De Boever, Frédéric Clément, Marie‐Ange Demoitié, Pascal Mettens, Philippe Moris, Edouard Ledent, Geert Leroux‐Roels, Opokua Ofori‐Anyinam
2012123
6
Safety and immunogenicity of candidate vaccine M72/AS01E in adolescents in a TB endemic setting
Vaccine ·Adam Penn‐Nicholson, Hennie Geldenhuys, Wivine Burny, Robbert van der Most, Cheryl L. Day, Erik Jongert, Philippe Moris, Mark Hatherill, Opokua Ofori‐Anyinam, Willem A. Hanekom, Anne Bollaerts, Marie‐Ange Demoitié, Angelique Kany Kany Luabeya, Evi De Ruymaeker, Michèle Tameris, Didier Lapierre, Thomas J. Scriba
201592
7
Comparison of the immunogenicity of the human papillomavirus (HPV)-16/18 vaccine and the HPV-6/11/16/18 vaccine for oncogenic non-vaccine types HPV-31 and HPV-45 in healthy women aged 18–45 years
Human Vaccines ·Mark H. Einstein, Mira Baron, Myron J. Levin, Archana Chatterjee, Bradley Fox, Sofia Scholar, Jeffrey B. Rosen, Nahida Chakhtoura, Marie Lebacq, Robbert van der Most, Philippe Moris, Sandra L. Giannini, Anne Schuind, Sanjoy Datta, Dominique Descamps
201190
8
The candidate tuberculosis vaccine Mtb72F/AS02A: Tolerability and immunogenicity in humans
Human Vaccines ·Kenneth Von Eschen, Royce A. Morrison, Madeleine Braun, Opokua Ofori‐Anyinam, Els De Kock, Priya Pavithran, Marguerite Koutsoukos, Philippe Moris, Daniel Cain, Marie‐Claude Dubois, Joe Cohen, W. Ripley Ballou
200989
9
Circumsporozoite-Specific T Cell Responses in Children Vaccinated with RTS,S/AS01E and Protection against P falciparum Clinical Malaria
PLoS ONE ·Ally Olotu, Philippe Moris, Jedidah Mwacharo, Johan Vekemans, Domtila Kimani, Michel Janssens, Oscar Kai, Erik Jongert, Marc Lievens, Amanda Leach, Tonya Villafana, Barbara Savarese, Kevin Marsh, Joe Cohen, Philip Bejon
201172
10
Antigen-Specific IL-2 Secretion Correlates with NK Cell Responses after Immunization of Tanzanian Children with the RTS,S/AS01 Malaria Vaccine
The Journal of Immunology ·Amir Horowitz, Julius Clemence R. Hafalla, Elizabeth C. King, John Lusingu, Denise Dekker, Amanda Leach, Philippe Moris, Joe Cohen, Johan Vekemans, Tonya Villafana, Patrick H. Corran, Philip Bejon, Chris J. Drakeley, Lorenz von Seidlein, Eleanor M. Riley
201272
11
Protective Immunity Induced with the RTS,S/AS Vaccine Is Associated with IL-2 and TNF-α Producing Effector and Central Memory CD4+ T Cells
PLoS ONE ·Joanne M. Lumsden, Robert Schwenk, Lisa Rein, Philippe Moris, Michel Janssens, Opokua Ofori‐Anyinam, Joe Cohen, Kent E. Kester, D. Gray Heppner, Urszula Krzych
201168
12
A Randomized, Controlled Dose-Finding Phase II Study of the M72/AS01 Candidate Tuberculosis Vaccine in Healthy PPD-Positive Adults
Journal of Clinical Immunology ·Jaime Montoya, Juan Antonio Solon, Soledad Rosanna C. Cunanan, Luz P. Acosta, Anne Bollaerts, Philippe Moris, Michel Janssens, Erik Jongert, Marie‐Ange Demoitié, Pascal Mettens, Salvacion Gatchalian, Carlota Vinals, Joe Cohen, Opokua Ofori‐Anyinam
201364
13
Immunogenicity and Safety of H5N1 A/Vietnam/1194/2004 (Clade 1) AS03-Adjuvanted Prepandemic Candidate Influenza Vaccines in Children Aged 3 to 9 Years
The Pediatric Infectious Disease Journal ·Javier Díez‐Domingo, María Garcés‐Sánchez, José‐María Baldó, María Victoria Planelles, Isabel Ubeda, Angels Jubert, Josep Marés, Philippe Moris, Pilar Garcı́a-Corbeira, Mamadou Dramé, Paul Gillard
201064
14
Safety and immunogenicity of the M72/AS01 E candidate tuberculosis vaccine in adults with tuberculosis: A phase II randomised study
Tuberculosis ·Paul Gillard, Pan‐Chyr Yang, Manfred Danilovitš, Wei‐Juin Su, Shih-Lung Cheng, Lea Pehme, Anne Bollaerts, Erik Jongert, Philippe Moris, Opokua Ofori‐Anyinam, Marie‐Ange Demoitié, Marcela Castro
201655
15
Adjuvant system AS02V enhances humoral and cellular immune responses to pneumococcal protein PhtD vaccine in healthy young and older adults: Randomised, controlled trials
Vaccine ·Isabel Leroux‐Roels, Jeanne‐Marie Devaster, Geert Leroux‐Roels, Vincent Verlant, Isabelle Henckaerts, Philippe Moris, Philippe Hermand, Pascale Van Belle, Jan Poolman, Pierre Vandepapelière, Yves Horsmans
201352
16
Safety and immunogenicity of an investigational 4-component Staphylococcus aureus vaccine with or without AS03 B adjuvant: Results of a randomized phase I trial
Human Vaccines & Immunotherapeutics ·Jack Lévy, Laurent Licini, Edwige Haelterman, Philippe Moris, Pascal Lestrate, Silvia Damaso, Pascale Van Belle, Dominique Boutriau
201552
17
Comparative humoral and cellular immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine in healthy women aged 18–45 years: Follow-up through Month 48 in a Phase III randomized study
Human Vaccines & Immunotherapeutics ·Mark H. Einstein, Myron J. Levin, Archana Chatterjee, Nahida Chakhtoura, Péter Takács, Grégory Catteau, Francis Dessy, Philippe Moris, Lan Lin, Frank Struyf, Gary Dubin
201450
18
Evaluation of the immune response to RTS,S/AS01 and RTS,S/AS02 adjuvanted vaccines
Human Vaccines & Immunotherapeutics ·Geert Leroux‐Roels, Isabel Leroux‐Roels, Frédéric Clément, Opokua Ofori‐Anyinam, Marc Lievens, Erik Jongert, Philippe Moris, W. Ripley Ballou, Joe Cohen
201445
19
Chemiluminescence assays of organophosphorus and carbamate pesticides
Analytica Chimica Acta ·Philippe Moris, Isabelle Alexandre, Marc Roger, José Remacle
199545
20
First-in-Human Randomized Study to Assess the Safety and Immunogenicity of an Investigational Respiratory Syncytial Virus (RSV) Vaccine Based on Chimpanzee-Adenovirus-155 Viral Vector–Expressing RSV Fusion, Nucleocapsid, and Antitermination Viral Proteins in Healthy Adults
Clinical Infectious Diseases ·Paola Cicconi, Claire Jones, Esha Sarkar, Laura Silva-Reyes, Paul Klenerman, Catherine de Lara, Claire Hutchings, Philippe Moris, Michel Janssens, Laurence Fissette, Marta Picciolato, Amanda Leach, A González‐López, Ilse Dieussaert, Matthew D. Snape
201943

About Philippe Moris

Philippe Moris is a scholar working on Epidemiology, Immunology, Infectious Diseases, Public Health, Environmental and Occupational Health and Molecular Biology, having authored 54 papers that have together received 2.8k indexed citations. Recurring topics across this work include Influenza Virus Research Studies (12 papers), Malaria Research and Control (12 papers), Tuberculosis Research and Epidemiology (10 papers), Immunotherapy and Immune Responses (10 papers), Respiratory viral infections research (10 papers), HIV Research and Treatment (8 papers), Hepatitis B Virus Studies (8 papers) and Mosquito-borne diseases and control (8 papers). The work is most often cited by research in Immunology (1.4k citations), Infectious Diseases (918 citations), Virology (205 citations), Epidemiology (1.3k citations) and Microbiology (140 citations). Philippe Moris has collaborated with scholars based in Belgium, United States and United Kingdom. Frequent co-authors include Opokua Ofori‐Anyinam, Emmanuel Hanon, Geert Leroux‐Roels, Joe Cohen, Frédéric Clément, Erik Jongert, Francis Dessy, Marie‐Ange Demoitié, Isabel Leroux‐Roels and Brigitte Colau. Their work appears in journals such as Vaccine, Human Vaccines & Immunotherapeutics, Tuberculosis, PLoS ONE and Clinical Infectious Diseases.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Patricia A. DarrahBreakdown of academic impact, for papers by Frédéric ClémentBreakdown of academic impact, for papers by Ricardo E. TasconBreakdown of academic impact, for papers by Donata MedagliniBreakdown of academic impact, for papers by Nigel TempertonBreakdown of academic impact, for papers by Susan L. BaldwinBreakdown of academic impact, for papers by Thomas EbensenBreakdown of academic impact, for papers by Tamara BerthoudBreakdown of academic impact, for papers by George H. LowellBreakdown of academic impact, for papers by Chikara Aizawa